Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia.
D000818:Animals; D001854:Bone Marrow Cells; D002454:Cell Differentiation / Q000187:drug effects; D002462:Cell Membrane / Q000502:physiology; D002478:Cells, Cultured; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D003115:Colony-Stimulating Factors / Q000494:pharmacology* / Q000627:therapeutic use; D003907:Dexamethasone / Q000494:pharmacology; D006023:Glycoproteins / Q000494:pharmacology*; D006098:Granulocytes / Q000166:cytology*; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007942:Leukemia, Experimental / Q000473:pathology; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D007962:Leukocytes / Q000166:cytology*; D008050:Lipid A / Q000494:pharmacology; D008264:Macrophages / Q000166:cytology*; D051379:Mice
D003115:Colony-Stimulating Factors; D006023:Glycoproteins; D008050:Lipid A; D003907:Dexamethasone